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Platelets play a central role in the pathogenesis of at-
herothrombosis.
1) Thus, achieving platelet inhibition is 
an important part of managing patients that have ex-
perienced an atherothrombotic event. Dual antiplatelet 
therapy with clopidogrel plus aspirin has been shown to 
markedly reduce ischemic events in patients undergoing 
percutaneous coronary intervention (PCI) and stenting.
2) 
Despite its proven benefit of dual antiplatelet therapy, 
diabetic patients remain at increased risk of recurrent 
ischemic events when compared to non-diabetic patients. 
Recent evidence suggests that diabetic patients are resis-
tant or partially responsive to treatments with a dual an-
tiplatelet effect (especially clopidogrel) which is related 
to poor clinical outcomes such as stent thrombosis and 
recurrent atherothrombotic events.
3)4) Yang et al.
5) previ-
ously reported that triple antiplatelet therapy (dual an-
tiplatelet plus cilostazol) results in more potent inhibi-
tion of adenosine diphosphase (ADP) induced platelet 
aggregation than dual antiplatelet therapy in patients 
with diabetes and drug-eluting stent (DES) implantation. 
These results suggest that triple antiplatelet therapy is a 
treatment option for amelioration of low responsiveness 
to clopidogrel in diabetes mellitus (DM).  
No treatments of clopidogrel low responsiveness in 
DM have been reported to date. An initial approach to 
clopidogrel low responsiveness was considered to be a 
correctable cause of resistance, including hyperglycemia, 
noncompliance, insulin resistance (metabolic syndrome) 
and drug interaction.   
Currently, practical strategies to overcome clopidogrel 
low responsiveness include 1) addition of cilostazol, 2) 
increasing the dose of antiplatelet agents, and 3) the use 




Cilostazol is a potent oral antiplatelet agent with a ra-
pid onset of action that selectively inhibits phosphodies-
terase III and increases cyclic adenosine mono phosphate 
(cAMP) levels in platelets. The increase in cAMP blocks 




7) of randomized crossover pla-
telet function study in patients with type 2 DM and cor-
onary artery disease following dual antiplatelet therapy 
revealed that the reduced platelet inhibition of P2Y12 
signaling can be enhanced by adjunctive treatment with 
cilostazol when compared with dual antiplatelet therapy. 
Thus, cilostazol led to significantly increased P2Y12 plate-
let inhibition, as measured by flow cytometry and light 
transmission aggregometry. These findings were similar 
to the results of a study conducted by Yang et al. Several 
clinical studies have shown that triple antiplatelet ther-
apy has better clinical outcomes than dual antiplatelet 
therapy in patients undergoing PCI and coronary stent-
ing.  
Lee et al.
8) compared the clinical benefit undergoing 
PCI between dual antiplatelet therapy (aspirin plus clo-
pidogrel or ticlopidine, group I, n=1,597) and triple an-
tiplatelet therapy (aspirin plus clopidogrel or ticlopidine 
plus cilostazol, group II, n=1,415) groups. They found 
that stent thrombosis within 30 days was significantly 
lower in group II (0.1%) than in group I (0.5%; p=0.024). 
Additionally, the independent predictors of stent throm-
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bosis were found to be primary stenting {hazard ratio 
(HR) 7.9, 95% confidence interval (CI) 2.0 to 30.8, p= 
0.003} and triple therapy (HR 0.12, 95% CI 0.015 to 
0.98, p=0.048). They concluded that triple antiplatelet 
therapy more effectively prevented thrombotic complica-
tions after stenting without an increased risk of side ef-
fects when compared to dual antiplatelet. These bench 
and clinical data indicated that adjunctive treatment 
with cilostazol may improve platelet inhibition in dia-
betic patients.   
 
Increasing Dose of Clopidogrel 
 
A recent study was conducted to evaluate the efficien-
cy of an 150 mg oral maintenance dose of clopidogrel.
9) 
Sixty patients that were pre-treated with 600 mg of clo-
pidogrel and had a successful PCI after 12 hours were in-
cluded in this trial. The patients were divided into groups 
that received one of two clopidogrel daily maintenance 
doses (75 or 150 mg) for 30 days in a double-blind ran-
domized manner. Platelet function was evaluated 30 
days after intervention by optical aggregometry and a 
VerifyNow P2Y12 assay. Administration of an 150 mg oral 
maintenance dose of clopidogrel resulted in more in-
tense inhibition of platelet aggregation than administra-
tion of the currently recommended 75 mg maintenance 
dose. An OPTIMUS study selectively examined type 2 
DM
10) and found that the use of a large maintenance dose 
resulted in higher platelet inhibition than the 75 mg 
clopidogrel maintenance dose. Large scale clinical data 
(CURRENT/OASIS 7) was recently presented at the 
European Society of Cardiology (ESC) 2009 meeting. 
These data indicated that doubling the loading and ma-
intenance doses of clopidogrel used to treat patients with 
acute coronary syndrome undergoing PCI significantly 
reduced stent thrombosis and cardiovascular events with-
out inducing a significant increase in major bleeding. 
These data suggest that increasing the dose of clopido-
grel may ensure an adequate platelet response. 
 
Use of New Thienopyridines 
 
Additional agents that might be potential alternatives 
to overcome the low responsiveness associated with clo-
pidogrel such as pasugrel,
11) AZD 6140 (ticagrelor)
12) and 
cangrelor
13) are currently being evaluated in clinical tri-
als. 
Prasugrel is a new thienopyridine derivative that pro-
duces more potent platelet inhibition and a rapid onset 
of action that is associated with irreversible P2Y12 receptor 
blockade. The latter properties of prasugrel may provide 
a superior alternative to clopidogrel, with less response 
variability and a decreased prevalence of non-respon-
siveness. Brandt et al.
11) compared the rate of onset, mag-
nitude, and consistency of platelet inhibition after ad-
ministration of prasugrel or clopidogrel to relate platelet 
inhibition to systemic exposure to each active metabolite. 
Inhibition of platelet aggregation after treatment with 
prasugrel was significantly higher (p<0.01) than after 
treatment with clopidogrel from 15 minutes through 24 
hours due to ADP induced platelet aggregation. More-
over, the response to prasugrel was more consistent than 
the response to clopidogrel. These results suggest that 
treatment with 60 mg prasugrel results in more rapid, 
potent, and consistent inhibition of platelet function 
than treatment with 300 mg clopidogrel. A TRITON-
TIMI 38 trial
14) compared the effects of prasugrel and 
clopidogrel in patients (n=13,608) with moderate to 
high risk acute coronary syndrome (ACS) who were un-
dergoing PCI. A composite end point of death, myo-
cardial infarction and stroke occurred in 12.1% of the 
clopidogrel group and 9.9% of the prasugrel group (HR: 
0.81, p<0.001). However, major bleeding occurred in 
1.8% of the clopidogrel group and 2.4% of the prasugrel 
group (HR 1.32, p=0.03). 
Ticagrelor is an oral and reversible P2Y12 receptor blo-
cker that does not require hepatic conversion to an ac-
tive metabolite and produces an overall superior ADP-
induced platelet inhibition with less response variability 
than clopidogrel. Ticagrelor has fast onset and offset ac-
tions that may be advantageous in patients who have 
to undergo immediate surgery.
12) A PLATO trial (n= 
18,624) was conducted to compare treatment with tica-
grelor (180 mg loading dose followed by 90 mg twice dai-
ly) to treatment with clopidogrel (300 to 600 mg load-
ing dose followed by 75 mg daily) for the prevention of 
cardiovascular events and the results were recently pres-
ented at the ESC 2009 meeting. The primary composite 
of death, myocardial infarction and stroke was found to 
be reduced from 11.7% to 9.8% (HR, 0.84; p<0.001). 
In addition, the total mortality was reduced from 5.9% 
to 4.5% (p<0.001). However, there was no difference in 
total major bleeding between the two groups (11.6% vs. 
11.2%; p=0.434). 
Treatment with new thienopyridines instead of clopi-
dogrel in patients with ACS or PCI may provide good 
results in cardiovascular disease (CVD) endpoints and 
potential alternatives to low responsiveness to clopidogrel. 
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